Event

Luca Richeldi

MD, PhD
Catholic University of the Sacred Heart;Università Cattolica del Sacro Cuore, Fondazione Policlinico A. Gemelli

Susanne Stowasser

M.D.
Boehringer Ingelheim Pharma GmbH & Co. KG

Marlies Wijsenbeek

MD, PhD
Erasmus MC, University Medical Centre;Erasmus Medical Center;Erasmus University Medical Center

Francesco Bonella

MD
Interstitial and Rare Lung Disease Unit, Ruhrlandklinik, University Hopsital, University of Duisburg

Christopher J. Ryerson

M.D.
Centre for Heart Lung Innovation, University of British Columbia;Univeristy of British Columbia and St. Paul's Hospital;University of British Columbia

Wibke Stansen

PhD
Boehringer Ingelheim Pharma GmbH & Co. KG

Paolo Spagnolo

MD PhD
UNIVERSITA STUDI DI PADOVA;Università degli Studi di Padova, Clinica di Malattie dell'Apparato Respiratorio;Universita Studi Di PAdova

Predicted Versus Observed Mortality in Clinical Trials of Nintedanib in Idiopathic Pulmonary Fibrosis (IPF)